1.36  -0.2 (-12.82%)		07-10 16:00
Open: 1.46 High: 1.5 Volume: 1,037,305		Pre. Close: 1.56 Low: 1.32 Market Cap: 80(M)

Short term
Mid term
Targets	6-month :	1.68	1-year :	1.93
Resists	First :	1.44	Second :	1.66
Pivot price	1.27
Supports	First :	1.1	Second :	0.91
MAs	MA(5) :	1.43	MA(20) :	1.24
	MA(100) :	1.21	MA(250) :	1.31
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	74	D(3) :	81.7
RSI	RSI(14): 55.6
52-week	High :	1.91	Low :	0.92

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ VANI ] has closed below upper band by 34.6%. Bollinger Bands are 91.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	1.5 - 1.51	1.51 - 1.52
Low:	1.3 - 1.31	1.31 - 1.32
Close:	1.35 - 1.36	1.36 - 1.37

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative implantable medical devices. The firm aims to address chronic diseases for which current treatments are insufficient or lacking. Its key initiatives include a portfolio of miniature drug implants, designed to ensure consistent and stable therapeutic drug delivery, as well as advanced implantable visual prostheses intended to provide meaningful artificial vision to blind individuals. Vivani Medical is headquartered in Emeryville, California.

Wed, 08 Jul 2026
Vivani Advances GLP-1 Implant Program With Novo Nordisk - The Globe and Mail

Tue, 07 Jul 2026
Vivani Medical to Merge Cortigent Into ClearOne; Receives 12.5M Shares, Deal Needs $10–15M Financing - TradingView

Tue, 07 Jul 2026
Novo Nordisk will evaluate Vivani’s semaglutide implant for weight loss - Stock Titan

Tue, 07 Jul 2026
Vivani Medical Enters into Agreement with Novo Nordisk to - GlobeNewswire

Fri, 03 Jul 2026
We're Keeping An Eye On Vivani Medical's (NASDAQ:VANI) Cash Burn Rate - Sahm

Thu, 02 Jul 2026
ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	86 (M)
Shares Float	36 (M)
Held by Insiders	57.9 (%)
Held by Institutions	6.5 (%)
Shares Short	379 (K)
Shares Short P.Month	393 (K)

EPS	-0.41
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.21
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-44.7 %
Return on Equity (ttm)	-176.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.32
Qtrly Earnings Growth	0 %
Operating Cash Flow	-25 (M)
Levered Free Cash Flow	-16 (M)

PE Ratio	-3.41
PEG Ratio	0
Price to Book value	6.18
Price to Sales	0
Price to Cash Flow	-4.63

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.